v3.24.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash $ 4,203,488 $ 5,353,392
Advances on research and development contract services 78,016 147,017
Prepaid insurance 17,116 49,224
Other prepaid expenses 10,000 11,350
Total current assets 4,308,620 5,560,983
Total assets 4,308,620 5,560,983
Current liabilities:    
Accounts payable and accrued expenses, including $36,250 and $46,982 to related parties at December 31, 2023 and 2022, respectively 156,758 230,734
Research and development contract liabilities 157,100 165,022
Total current liabilities 313,858 395,756
Commitments and contingencies  
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290 shares and 1,664,706 shares at December 31, 2023 and 2022, respectively 225 166
Additional paid-in capital 48,976,265 45,059,760
Accumulated deficit (48,481,728) (43,394,699)
Total stockholders’ equity 3,994,762 5,165,227
Total liabilities and stockholders’ equity $ 4,308,620 $ 5,560,983

Source

HTML PDF
ZIP